clinical trial · NCT07182591
A Study of DS5361b in Participants With Advanced Solid Tumors
Daiichi Sankyo·phase1·recruiting·n = 192
Advanced Solid TumorDS5361bPembrolizumab
brief summary
This study aims to assess the safety, tolerability, and preliminary efficacy and to determine the MTD of DS5361b in monotherapy and combination with pembrolizumab in participants with advanced or metastatic solid tumors.
started
Oct 2, 2025
primary completion
Mar 18, 2030
completion
Dec 3, 2030
last updated
Mar 20, 2026
official title
A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS5361b in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol